Watch Chris Baldwin, Deputy CEO of Exopharm (ASX:EX1), as he explains about the Exopharm’s latest developments and potential target markets. 0:00 – Intro 0:10 – What...
The focus on digital health has become a global trend. The long-term benefits of technological adaptation in this space will most likely be a reduction in...
Watch Jon Pilcher, CEO of Neuren Pharmaceuticals (ASX:NEU), speaking about Neuren’s area of drug focus and the latest updates on the Trofinetide development. 0:11 – Firstly,...
StockPal spoke to Jason van Schie, Managing Director of People Diagnostix, a B2B Software-as-a-Service company in the school and workspace preventative mental health space. In this...
2020 was a year for reinvigorating Avecho Biotechnology Limited (ASX:AVE) – cementing Company’s the rebrand, a change in CEO and a consolidated portfolio of products. Here...
ASX cannabis stocks are gaining momentum, stimulated by significant developments in the global regulatory environments in recent months. On the cusp of a potential rerate is...
Last week, Creso Pharma Limited’s (ASX:CPH; FRA: 1X8) wholly-owned Canadian cannabis cultivation subsidiary, Mernova Medicinal Inc. received three purchase orders with a combined value of C$275,023...
